首页> 外文期刊>Oncology letters >Expression of tumor-associated calcium signal transducer 2 in patients with salivary adenoid cystic carcinoma: Correlation with clinicopathological features and prognosis.
【24h】

Expression of tumor-associated calcium signal transducer 2 in patients with salivary adenoid cystic carcinoma: Correlation with clinicopathological features and prognosis.

机译:涎腺腺样囊性癌患者肿瘤相关钙信号转导子2的表达:与临床病理特征和预后的关系。

获取原文
获取原文并翻译 | 示例
       

摘要

Salivary adenoid cystic carcinoma (SACC) is a common salivary malignancy. The current treatment option for SACC is complete surgical excision with postoperative radiotherapy. The prognosis remains unsatisfactory, due to frequent local recurrence and distant metastases that directly reduce the overall survival time. Previous studies have shown that overexpression of tumor-associated calcium signal transducer 2 (TACSTD2) is associated with poor prognosis in various human epithelial cancers. The expression of TACSTD2 in SACC is currently unknown. The present study therefore aimed to retrospectively investigate TACSTD2 protein expression by immunohistochemistry on paraffin-embedded primary tumor tissue samples from a series of consecutive SACC patients (n=81). The correlation of TACSTD2 expression with clinicopathological variables was evaluated using either the Kruskal-Wallis or Mann-Whitney statistical tests. The survival curves were plotted using the Kaplan-Meier method. The parameters of prognostic significance found by univariate analysis were verified in a multivariate Cox regression model. Overexpression of TACSTD2 was detected in 35/81 (44%) SACC patients and was significantly associated with a decreased overall survival (P<0.01). Univariate analysis showed that TACSTD2 overexpression was correlated with TNM stage (P=0.020), local recurrence (P=0.002) and distant metastasis (P=0.001). Multivariate analyses further revealed that TACSTD2 may be an independent prognostic indicator. In conclusion, TACTSD2 could be recognized as an independent prognostic indicator for SACC. Gene therapy targeting TACSTD2 may be a possible treatment approach for patients with SACC overexpressing this cell-surface marker.
机译:涎腺腺样囊性癌(SACC)是常见的涎腺恶性肿瘤。 SACC的当前治疗选择是术后放射疗法进行完全手术切除。由于频繁的局部复发和远处转移直接减少了总生存时间,因此预后仍然不理想。先前的研究表明,与肿瘤相关的钙信号转导子2(TACSTD2)的过表达与各种人类上皮癌的不良预后有关。 TACSTD2在SACC中的表达目前未知。因此,本研究旨在通过免疫组织化学方法对来自一系列连续SACC患者(n = 81)的石蜡包埋的原发肿瘤组织样品进行TACSTD2蛋白表达的回顾性研究。使用Kruskal-Wallis或Mann-Whitney统计检验评估TACSTD2表达与临床病理变量的相关性。使用Kaplan-Meier方法绘制存活曲线。在多元Cox回归模型中验证了通过单因素分析发现的预后意义参数。在35/81(44%)SACC患者中检测到TACSTD2过表达,并且与总生存期降低显着相关(P <0.01)。单因素分析表明TACSTD2过表达与TNM分期(P = 0.020),局部复发(P = 0.002)和远处转移(P = 0.001)相关。多变量分析进一步表明,TACSTD2可能是独立的预后指标。总之,TACTSD2可被视为SACC的独立预后指标。针对过表达该细胞表面标志物的SACC患者,靶向TACSTD2的基因治疗可能是一种可能的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号